-+ 0.00%
-+ 0.00%
-+ 0.00%

Baird Upgrades Tandem Diabetes Care to Outperform, Raises Price Target to $30

Benzinga·12/16/2025 11:25:38
Listen to the news
Baird analyst Jeff Johnson upgrades Tandem Diabetes Care (NASDAQ:TNDM) from Neutral to Outperform and raises the price target from $18 to $30.